Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Cell line study of nucleosome-based biomarkers in the diagnosis and detection of relapses in glioblastoma

Tuesday, October 24, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The study presented at ESMO 2023 focuses on nucleosome-based biomarkers for diagnosing and detecting relapses in glioblastoma. Conducted by Decarpentrie et al., the research aims to enhance the prognostic capabilities of current cancer tests. This innovative approach could lead to improved patient outcomes through better monitoring.
Price reaction · baseline $16.632 (2023-10-23 close) · hit pre-market · 3 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-3.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation at ESMO 2023 highlights innovative research.
  • Focus on nucleosome-based biomarkers shows potential in glioblastoma detection.
  • Study may improve diagnosis and monitoring of relapses in patients.

Full Press Release Details

Poster title: “Cell line study of nucleosome-based biomarkers in the diagnosis and detection of relapses in glioblastoma.”
Presented at: ESMO 2023
Decarpentrie et al

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What was the focus of the study presented at ESMO 2023?

The study focused on nucleosome-based biomarkers for diagnosing and detecting glioblastoma relapses.

Who conducted the research on glioblastoma biomarkers?

The research was conducted by Decarpentrie et al.

What potential benefits do nucleosome biomarkers offer?

Nucleosome biomarkers may improve diagnosis and monitoring of glioblastoma relapses.

Where was the study on glioblastoma biomarkers presented?

The study was presented at the ESMO 2023 conference.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare glioblastoma nucleosome biomarkers ESMO 2023
Last updated: Oct 24, 2023

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk